Milestone Pharmaceuticals... (MIST)
2.06
-0.07 (-3.29%)
At close: Feb 20, 2025, 3:59 PM
2.08
0.73%
After-hours: Feb 20, 2025, 06:20 PM EST
undefined% (undefined)
| Bid | 2.02 |
| Market Cap | 110.12M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.8 |
| PE Ratio (ttm) | -2.58 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.08 |
| Volume | 712,911 |
| Avg. Volume (20D) | 633,057 |
| Open | 2.11 |
| Previous Close | 2.13 |
| Day's Range | 2.02 - 2.13 |
| 52-Week Range | 1.12 - 2.75 |
| Beta | undefined |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and ...
Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2019
Employees 47
Stock Exchange NASDAQ
Ticker Symbol MIST
Website https://www.milestonepharma.com
Analyst Forecast
According to 3 analyst ratings, the average rating for MIST stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 335.84% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
6 months ago
+2.86%
Milestone Pharmaceuticals shares are trading highe...
Unlock content with
Pro Subscription
